产后使用阿司匹林与作为母亲心脏健康标志物的NT-proBNP水平之间的关联:一项随机对照试验
该双盲随机对照试验将110名有子痫前期风险的患者按1:1随机分配至产后继续使用低剂量阿司匹林81 mg组或安慰剂组,疗程6周。主要结局产后随访时NT-proBNP水平在两组间无差异(中位数36.5 vs 39.5 ng/mL,P=.49)。产后子痫前期发生率在阿司匹林组数值上较低但无统计学显著差异(5.6% vs 12.7%,P=.32)。
要点
- 产后继续使用低剂量阿司匹林81 mg 6周未降低NT-proBNP水平。
- 产后子痫前期发生率阿司匹林组5.6% vs 安慰剂组12.7%,无统计学显著差异。
- 两组再入院率和出血并发症发生率相似,无产后子痫或输血病例。
核心结论
- 与安慰剂相比,产后继续使用低剂量阿司匹林未与NT-proBNP水平降低相关。
- 需要更多有足够把握度检测母亲结局差异的研究来评估低剂量阿司匹林在产后期的作用。
研究设计与样本
- 双盲随机对照试验,纳入有子痫前期风险的患者,按1:1比例随机分配至低剂量阿司匹林81 mg组或安慰剂组,产后用药6周。
- 计划样本量110名参与者(因预期产后随访丢失),检测NT-proBNP临床显著差异所需样本量为90名(80%把握度)。
- 2023年7月至2024年5月期间,110名参与者被随机分配至低剂量阿司匹林组(n=55)或安慰剂组(n=55)。
- 主要结局为产后随访时的NT-proBNP水平,使用Wilcoxon秩和检验比较。
- 预设次要结局包括产后子痫前期、子痫、再入院、启动或调整降压药物以及输血,以计数(百分比)报告,经Bonferroni校正多重检验后使用Fisher精确检验比较。
主要发现
- 主要结局NT-proBNP水平两组间无差异(中位数[四分位距],36.5 [36.0-61.0] vs 39.5 [36.0-74.0] ng/mL;P=.49)。
- 随机分配至低剂量阿司匹林组 vs 安慰剂组的产后子痫前期发生率(5.6% vs 12.7%;P=.32)数值上较低但无统计学显著差异。
- 两组再入院率和出血并发症发生率相似。
- 无产后子痫或输血病例。
- 基线人口学特征两组间相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多有足够把握度检测母亲结局差异的研究来评估低剂量阿司匹林在产后期的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During pregnancy, administration of low-dose aspirin 81 mg (LDA) has been demonstrated to decrease the incidence of preeclampsia in at-risk individuals. However, the role of continuation of LDA in the postpartum period and its association with long-term maternal health outcomes is unknown. OBJECTIVE: This study aimed to compare levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide), a marker of cardiac strain, and clinical outcomes between patients at risk of preeclampsia randomly assigned to continuation of low-dose aspirin and those who received placebo for 6 weeks postpartum. STUDY DESIGN: This double-blinded randomized controlled trial included patients at risk of preeclampsia randomly assigned in a 1:1 ratio to low-dose aspirin (81 mg) or placebo for 6 weeks postpartum. The primary outcome was NT-proBNP levels at the postpartum visit. A sample size of 90 was required to detect a clinically significant difference in NT-proBNP between low-dose aspirin and placebo with 80% power. A sample size of 110 participants was planned because of anticipated loss to follow-up in the postpartum period. Prespecified secondary outcomes were postpartum preeclampsia, eclampsia, hospital readmission, initiation or titration of blood pressure medications, and blood transfusion. The primary outcome was compared using the Wilcoxon rank sum test. Secondary outcomes are reported as count (percentage) and were compared using the Fisher exact test after adjusting for multiple testing using Bonferroni correction. RESULTS: From July 2023 to May 2024, 110 participants were randomly assigned to low-dose aspirin (n=55) or placebo (n=55). Baseline demographics were similar between groups. There was no difference in the primary outcome of NT-proBNP levels between groups (median [interquartile range], 36.5 [36.0-61.0] vs 39.5 [36.0-74.0] ng/mL; P=.49). Rates of postpartum preeclampsia among patients randomly assigned to low-dose aspirin vs placebo (5.6% vs 12.7%; P=.32) were numerically but not statistically significantly lower, with similar rates of hospital readmission and bleeding complications. There were no cases of postpartum eclampsia or blood transfusion. CONCLUSION: Continuation of low-dose aspirin after delivery was not associated with decreased NT-proBNP levels compared with placebo. Additional studies powered to detect differences in maternal outcomes are needed to evaluate the role of low-dose aspirin in the postpartum period.
引用
- Watkins VY, Melendez Torres AE, Prado MC, et al. The association between postpartum aspirin use and NT-proBNP levels as a marker for maternal cardiac health: a randomized controlled trial. Am J Obstet Gynecol. 2025. PMID: 40653065. doi:10.1016/j.ajog.2025.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。